Madrigal Pharmaceuticals, Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging +5.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-2.55 | $-1.99 | +22.0% | Beat | Q2 FY26 call |
| Q1 FY26 | $-3.61 | $-3.25 | +10.0% | Beat | |
| Q3 FY25 | not reported | $-5.08 | not reported | not reported | |
| Q2 FY25 | $-3.48 | $-1.90 | +45.4% | Beat | Q2 FY25 call |
| Q1 FY25 | $-3.62 | $-3.32 | +8.3% | Beat | |
| Q4 FY24 | $-4.12 | $-2.71 | +34.2% | Beat | |
| Q3 FY24 | $-6.94 | $-4.92 | +29.1% | Beat | |
| Q2 FY24 | $-7.55 | $-7.10 | +6.0% | Beat | |
| Q1 FY24 | $-6.06 | $-7.38 | -21.8% | Miss | |
| Q4 FY23 | $-5.32 | $-5.68 | -6.8% | Miss | |
| Q3 FY23 | $-4.78 | $-5.34 | -11.7% | Miss | |
| Q2 FY23 | $-4.47 | $-4.69 | -4.9% | Miss |
Back to MDGL overview · MDGL holders · MDGL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.